cloudfront

Report Detail



Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview

              Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment

                            Assessment by Mechanism of Action

                              Assessment by Route of Administration

                                Assessment by Molecule Type

                                  Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development

                                    AbbVie Inc

                                      Abeome Corp

                                        Alligator Bioscience AB

                                          Apogenix AG

                                            BioInvent International AB

                                              Bristol-Myers Squibb Co

                                                Denceptor Therapeutics Ltd

                                                  GigaGen Inc

                                                    GlaxoSmithKline Plc

                                                      Incyte Corp

                                                        Innovent Biologics Inc

                                                          Invenra Inc

                                                            Kyowa Hakko Kirin Co Ltd

                                                              MedImmune LLC

                                                                Pfizer Inc

                                                                  Zai Lab Ltd

                                                                    Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles

                                                                      ABBV-368 - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              ABM-193 - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      ATOR-1015 - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              Bispecific Monoclonal Antibodies to Agonize TNFRSF4 for Oncology - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      BMS-986178 - Drug Profile

                                                                                                        Product Description

                                                                                                          Mechanism Of Action

                                                                                                            R&D Progress

                                                                                                              durvalumab + tavolimab - Drug Profile

                                                                                                                Product Description

                                                                                                                  Mechanism Of Action

                                                                                                                    R&D Progress

                                                                                                                      Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile

                                                                                                                        Product Description

                                                                                                                          Mechanism Of Action

                                                                                                                            R&D Progress

                                                                                                                              Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile

                                                                                                                                Product Description

                                                                                                                                  Mechanism Of Action

                                                                                                                                    R&D Progress

                                                                                                                                      GSK-3174998 - Drug Profile

                                                                                                                                        Product Description

                                                                                                                                          Mechanism Of Action

                                                                                                                                            R&D Progress

                                                                                                                                              HuOHX-10 - Drug Profile

                                                                                                                                                Product Description

                                                                                                                                                  Mechanism Of Action

                                                                                                                                                    R&D Progress

                                                                                                                                                      IBI-101 - Drug Profile

                                                                                                                                                        Product Description

                                                                                                                                                          Mechanism Of Action

                                                                                                                                                            R&D Progress

                                                                                                                                                              INCAGN-1949 - Drug Profile

                                                                                                                                                                Product Description

                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                    R&D Progress

                                                                                                                                                                      KHK-4083 - Drug Profile

                                                                                                                                                                        Product Description

                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                            R&D Progress

                                                                                                                                                                              Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

                                                                                                                                                                                Product Description

                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                      Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile

                                                                                                                                                                                        Product Description

                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                              Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile

                                                                                                                                                                                                Product Description

                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                      MSB-013 - Drug Profile

                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                              OrthomAb - Drug Profile

                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                      PF-04518600 - Drug Profile

                                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                                              SCB-340 - Drug Profile

                                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                                      tavolimab - Drug Profile

                                                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                                                              tavolimab + tremelimumab - Drug Profile

                                                                                                                                                                                                                                                Product Description

                                                                                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                                                                                      ZL-1101 - Drug Profile

                                                                                                                                                                                                                                                        Product Description

                                                                                                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                                                                                                            R&D Progress

                                                                                                                                                                                                                                                              Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products

                                                                                                                                                                                                                                                                Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products

                                                                                                                                                                                                                                                                  Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones

                                                                                                                                                                                                                                                                    Featured News & Press Releases

                                                                                                                                                                                                                                                                      Jul 25, 2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101

                                                                                                                                                                                                                                                                        Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody

                                                                                                                                                                                                                                                                          Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation

                                                                                                                                                                                                                                                                            Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015

                                                                                                                                                                                                                                                                              Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015

                                                                                                                                                                                                                                                                                May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015

                                                                                                                                                                                                                                                                                  Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4

                                                                                                                                                                                                                                                                                    Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

                                                                                                                                                                                                                                                                                      Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

                                                                                                                                                                                                                                                                                        Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

                                                                                                                                                                                                                                                                                          Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment

                                                                                                                                                                                                                                                                                            Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy

                                                                                                                                                                                                                                                                                              Appendix

                                                                                                                                                                                                                                                                                                Methodology

                                                                                                                                                                                                                                                                                                  Coverage

                                                                                                                                                                                                                                                                                                    Secondary Research

                                                                                                                                                                                                                                                                                                      Primary Research

                                                                                                                                                                                                                                                                                                        Expert Panel Validation

                                                                                                                                                                                                                                                                                                          Contact Us

                                                                                                                                                                                                                                                                                                            Disclaimer

                                                                                                                                                                                                                                                                                                            Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

                                                                                                                                                                                                                                                                                                            Summary

                                                                                                                                                                                                                                                                                                            Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

                                                                                                                                                                                                                                                                                                            The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

                                                                                                                                                                                                                                                                                                            Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response.

                                                                                                                                                                                                                                                                                                            OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 2, 5 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hematological Tumor, Hepatitis B, Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

                                                                                                                                                                                                                                                                                                            Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

                                                                                                                                                                                                                                                                                                            Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                                                                            Scope

                                                                                                                                                                                                                                                                                                            - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
                                                                                                                                                                                                                                                                                                            - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                                                                                                                                                                                                                                            - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                                                                                                                                                                                                                                            - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                                                                                                                                                                                                                                            - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
                                                                                                                                                                                                                                                                                                            - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                                                                                                                                                                                                                                            - The report summarizes all the dormant and discontinued pipeline projects
                                                                                                                                                                                                                                                                                                            - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

                                                                                                                                                                                                                                                                                                            Reasons to buy

                                                                                                                                                                                                                                                                                                            - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                                                                                                                                                                                                                                            - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                                                                                                                                                                                                                                            - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
                                                                                                                                                                                                                                                                                                            - Identify the use of drugs for target identification and drug repurposing
                                                                                                                                                                                                                                                                                                            - Identify potential new clients or partners in the target demographic
                                                                                                                                                                                                                                                                                                            - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                                                                                                                                                                                                                                            - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                                                                                                                                                                                                                                            - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
                                                                                                                                                                                                                                                                                                            - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




                                                                                                                                                                                                                                                                                                            Summary:
                                                                                                                                                                                                                                                                                                            Get latest Market Research Reports on Tumor Necrosis . Industry analysis & Market Report on Tumor Necrosis is a syndicated market report, published as Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Tumor Necrosis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


                                                                                                                                                                                                                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                                                                            Purchase this Report

                                                                                                                                                                                                                                                                                                            $3,500.00
                                                                                                                                                                                                                                                                                                            $7,000.00
                                                                                                                                                                                                                                                                                                            $10,500.00
                                                                                                                                                                                                                                                                                                            2,350.25
                                                                                                                                                                                                                                                                                                            4,700.50
                                                                                                                                                                                                                                                                                                            7,050.75
                                                                                                                                                                                                                                                                                                            3,220.70
                                                                                                                                                                                                                                                                                                            6,441.40
                                                                                                                                                                                                                                                                                                            9,662.10
                                                                                                                                                                                                                                                                                                            423,990.00
                                                                                                                                                                                                                                                                                                            847,980.00
                                                                                                                                                                                                                                                                                                            1,271,970.00
                                                                                                                                                                                                                                                                                                            232,096.90
                                                                                                                                                                                                                                                                                                            464,193.80
                                                                                                                                                                                                                                                                                                            696,290.70
                                                                                                                                                                                                                                                                                                            Add To Cart Credit card Logo

                                                                                                                                                                                                                                                                                                            Related Reports


                                                                                                                                                                                                                                                                                                            Reason to Buy

                                                                                                                                                                                                                                                                                                            Request for Sample of this report